N-Acetyl Selank — Deep Research (Cognitive & Nootropic)

Published · Researched 2026-09-21

Research file written 2026-09-21. Social-first methodology: community sources weighted before vendor pages.

1. Overview

N-Acetyl Selank (sold as "Selank N-Acetyl Amidate" or "NA-Selank") is a synthetic analog of Selank — the same Thr-Lys-Pro-Arg-Pro-Gly-Pro backbone with an N-terminal acetyl group and a C-terminal amide (Ac-Thr-Lys-Pro-Arg-Pro-Gly-Pro-NH₂), molecular weight 793.92 g/mol, CAS 2212313-10-6 (Protide Health product data, 2026). Like N-Acetyl Semax, the modifications are a design trick borrowed from peptide chemistry: acetylation and amidation block the endopeptidase attack that degrades unmodified Selank, and vendors claim a 200–300-minute half-life and systemic (subcutaneous/injectable) activity instead of the native peptide's intranasal orientation (PeptidePub 2026 buyer guide; AtlasPeptide Medium guide, 2026).

Key caution: all the human research on Selank's anxiolytic and nootropic effects used the native, unmodified molecule. The N-acetyl analog rides on that evidence file without having generated its own controlled human data (UNVERIFIED analog-specific efficacy; Medium/Pubmed cross-checks found no primary controlled human study of the acetylated analog). Community discussion of this variant is thin — almost all "Selank" anecdotes are about the native molecule.

2. Social standing

A marginal SKU, not a community staple. The June-2026 GitHub hukus/llimitless category scan ranks native Selank as a strongest-anecdote node but contains no meaningful N-acetyl-Selank anecdote trail. A dedicated PeptidePub buyer guide ("Selank Nasal Spray vs Vial vs N-Acetyl Selank Amidate," Medium, 2026) exists, which at least proves the SKU is established enough for a publisher to write a format guide — it positions the amidated analog as the "injectable/long half-life" option, but acknowledges the native molecule carries the research file.

• Threads: the 2026-07-24 @ganee self-trial log (26 likes, 28 replies) describes spilling part of a Selank bottle — no evidence this was the acetylated analog; no acetylated-specific owner reports surfaced in Threads searches this round.
• Facebook Groups: the four groups queried this round returned zero indexed hits for Selank at all, acetylated or otherwise (query-index limitation, not evidence of absence).
• Recurring community question: whether the acetylated analog is "stronger/longer-lasting" — vendors answer yes; no independent verification found.
• Overhyped warnings: the claimed 200–300-minute half-life and "systemic vs. intranasal" superiority narrative is vendor marketing repeated by buyers; UNVERIFIED — no primary controlled human source was found for the analog's pharmacokinetics.

3. Social validation — Tier 3 / UNVALIDATED — included for comparison, low community signal

• Vendor-publisher literature (PeptidePub Medium buyer guide, 2026; Brainflow Selank-vs-Semax guide): proves the SKU exists as an established commercial variant and how vendors position it against native Selank (longer half-life, injectable). Proves commercial existence, not community endorsement.
• Vendor product data (Protide Health, Ameano, Polaris, Peptides.org/AMP): proves multi-vendor availability with stated identity (sequence, MW, CAS) and COA claims. Proves market presence.
• Missing: no named Facebook Group posts, no Threads owner content, no forum experience threads, no independent reviews of the acetylated analog were found this round. Native Selank's deep anecdote trail cannot be transferred automatically to this analog — different molecule, different pharmacokinetics, no human data.
• Gap: the highest-signal platforms (Facebook Groups, Instagram owner content, Threads) contributed nothing acetylated-specific this round.

4. Key specs table

5. Pricing (observed 2026-09-20/21)

Marketplace used range: not observed — report honestly, no used-market data found. For context, native Selank nasal sprays/vials sit in a similar $30–75 band, so the analog is priced at the top of the Selank line without the native molecule's evidence file.

6. What's included / what's needed

• Lyophilized vial ships as powder; reconstitution solution (bacteriostatic water) typically sold separately.
• Subcutaneous use (per vendor positioning) would require insulin syringes and alcohol pads — but no dosing protocol exists in any research literature; all dosing is community folklore, not guidance.

7. Support reality

• COA culture: Ameano's current batch page had the COA "not yet posted" at observation — a real-world example of the gap between claimed testing and published certificates. Protide publishes sequence/MW/CAS identity data.
• Quality risk: wholesale listings at $4–10/vial (MOQ 10) are the classic provenance gamble — identity, purity, and endotoxin risk with no chain of custody.
• Label risk: "Selank" products that are actually the acetylated/amidated analog (or blends) are documented in 2026 buyer guides; buyers seeking the researched native molecule may receive this analog instead.

8. Community verdict

Almost nobody in the community discusses this analog on its own merits — the Selank conversation is overwhelmingly about the native molecule. Vendors sell it as "Selank but longer-lasting and injectable," but the only evidence that matters (human trials) belongs to the native molecule, and the analog's headline specs (200–300-min half-life) come from vendor copy, not published research. It is a research chemical with an UNVERIFIED pharmacokinetic story riding a native molecule's reputation.

9. Regulatory & safety status

• USA/EU: not FDA or EMA approved; sold as a research chemical not for human use. No established human toxicology, no controlled human trials of the analog.
• Russia: only native Selank has any medical-registration history there; the acetylated analog has no registered-medicine status anywhere found.
• Community-reported side effects: none specific to the analog documented in this session's extraction (no analog-specific review footprint found).

Images

No real product photos available. No N-Acetyl Selank images were captured in this session (0/8 views present in img/); vendor listing images were not verifiably captured as distinct real photos. Do not treat the absence of photos as a data point about the compound.

Not medical advice. This is community research, not a recommendation. N-Acetyl Selank is an unapproved research chemical with no human safety data; it is not for human use. Talk to a clinician before considering any peptide.

Named sources

• Protide Health product data — Sequence: Ac-Thr-Lys-Pro-Arg-Pro-Gly-Pro-NH₂ (2026)
• Vendor consensus — Modifications: N-terminal acetylation + C-terminal amidation
• Vendor marketing — Claimed half-life: 200–300 minutes — UNVERIFIED**, no primary controlled human source found
• PeptidePub buyer guide — Route (vendor positioning): Subcutaneous/injectable (vs. native Selank's intranasal) (2026)
• Threads @ganee — the 2026-07-24 @ganee self-trial log (26 likes, 28 replies) describes spilling part of a *Selank* bottle — no evidence this was the acetylated analog; no acetylated-specific owner reports surfaced in Threads searches this round. (2026-07-24)
• AtlasPeptide Medium guide — Like N-Acetyl Semax, the modifications are a design trick borrowed from peptide chemistry: acetylation and amidation block the endopeptidase attack that degrades unmodified Selank, and vendors claim a 200–300-minute half-life and systemic…
• Brainflow Selank-vs-Semax guide — **Vendor-publisher literature (PeptidePub Medium buyer guide, 2026; Brainflow Selank-vs-Semax guide):** proves the SKU exists as an established commercial variant and how vendors position it against native Selank (longer half-life, injectable). (2026)

Source URLs were not recorded for these references.